Artificial Intelligence | News | Insights | AiThority
[bsfp-cryptocurrency style=”widget-18″ align=”marquee” columns=”6″ coins=”selected” coins-count=”6″ coins-selected=”BTC,ETH,XRP,LTC,EOS,ADA,XLM,NEO,LTC,EOS,XEM,DASH,USDT,BNB,QTUM,XVG,ONT,ZEC,STEEM” currency=”USD” title=”Cryptocurrency Widget” show_title=”0″ icon=”” scheme=”light” bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ custom-css-class=”” custom-id=”” css=”.vc_custom_1523079266073{margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”]

Daily AI Roundup: Biggest Machine Learning, Robotic And Automation Updates 1st Sept 2023

This is our AI Daily Roundup . We are covering the top updates from around the world. The updates will feature state-of-the-art capabilities in artificial intelligence (AI)Machine Learning, Robotic Process Automation, Fintech, and human-system interactions. We cover the role of AI Daily Roundup and its application in various industries and daily lives.

ChatGPT Dominates LLM Mentions on Social Media in 2023, Bards Distant Second, Reveals GlobalData

In the dynamic landscape of artificial intelligence (AI) large language models (LLMs), OpenAI’s ChatGPT has emerged as the frontrunner with an impressive 89.9% share of voice on platforms like Twitter and Reddit among the top seven LLMs during 2023, reveals the Social Media Analytics Platform of GlobalData, a leading data and analytics company.

BrainChip and Tata Elxsi Partner to Provide Intelligent, Ultralow-Power Solutions

BrainChip Holdings Ltd, the world’s first commercial producer of ultra-low power, fully digital, event-based, neuromorphic AI IP, welcomes leading design and technology services provider Tata Elxsi as a partner to its Essential AI ecosystem.

Zeta Launches Customer Growth Intelligence, a Snowflake Native App in the Data Cloud

Related Posts
1 of 40,972

Zeta Global, the AI-Powered Marketing Cloud, announced it has launched a new Snowflake Native App, Customer Growth Intelligence (CGI), on Snowflake Marketplace. This new offering enhances and extends the deep integration between the two companies sharing a vision to reinvent how enterprises ingest, store, synthesize, surface, and activate consumer data to make complex solutions simpler for marketers.

Allegheny County District Attorney’s Office to Deploy NICE AI-Powered Digital Evidence Management Solution

NICE announced that the Office of the District Attorney of Allegheny County (which includes the Pittsburgh, Pennsylvania metropolitan area) will be deploying NICE Justice, one of the AI-powered solutions in NICE’s Evidencentral platform, to streamline its entire criminal justice process. Through its deployment of NICE Justice, the Allegheny County District Attorney’s Office is looking to improve how it manages a growing influx of digital evidence across every touchpoint, from intake to discovery. The Allegheny County DA serves a population of 1.2 million people and is the second county District Attorney’s office in Pennsylvania to select NICE Justice.

Lantern Pharma Expands AI Capabilities of RADR Platform to Accelerate the Clinical Development of Immune Checkpoint Inhibitors

Lantern Pharma, an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary AI and machine learning (ML) platform, RADR, with multiple clinical stage drug programs,  announced a substantial increase in the power and capabilities of RADR focused on improving the drug development process for immune checkpoint inhibitors (ICIs). These capabilities are expected to address the multiple challenges facing the increased usage of ICIs in cancer therapy. Since gaining regulatory approval in 2011, ICIs have improved the lives of tens of thousands of cancer patients as either monotherapies, and more recently, in combination regimens with other therapies. The success of ICIs has resulted in multiple competing ICI molecules, often from the same class, in overlapping cancer indications. Additionally, recent clinical trial failures reveal headwinds to the desired expansion of ICIs for a broader range of cancers and patient groups. Currently, there are over 5,200 ongoing clinical trials involving ICIs, many of these lacking adequate biomarker strategies or guidance from AI enabled approaches to optimize the selection of patient responder populations.

 [To share your insights with us, please write to sghosh@martechseries.com] 

Comments are closed.